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Abstract
Background: Barrett’s esophagus (BE) is a disease with a rising prevalence in western countries probably due to
the unhealthy lifestyle. In significant number of cases it develops to esophageal adenocarcinoma. Two decades
ago, important gene regulators (microRNAs) were discovered and their attendance in the process of malignant
transformation was demonstrated (e.g. miR-192, 196a, 203). Our aim was to select the patients with the increased
risk of malignant transformation before the cancer develops.
Methods: 71 patients with BE disease were selected, slides from FFPE blocks were prepared, the lesions were
microdissected and a qPCR relative expression analysis for selected microRNAs (generally known to be connected
with malignant transformation process) was carried out.
Results: We demonstrated unequivocal statistically significant upregulation of two microRNAs (miR-192, 196a) and
downregulation of miR-203 and positive miR-196a correlation with progression from intestinal metaplasia to
adenocarcinoma compared to normal individuals.
Conclusions: We hypothetize that there do exist changes of selected microRNAs which can undoubtedly
distinguish the patients with BE from normal healthy individuals.
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Background
Barrett’s esophagus
Barrett’s esophagus (BE) is the gastrointestinal disorder
termed after the physician Norman Barrett in the 1950s
[1]. It is an infliction of a distal part of the esophageal
mucosa. In physiological state, esophageal mucosa is
lined by squamous stratified nonkeratinized epithelium.
However, by the influence of several agents the squa-
mous epithelium is being replaced by the columnar one,
the phenomenon known as metaplasia [2]. Subjectively,
the patient with BE can suffer from heartburn, eructa-
tion or nausea, nevertheless, sometimes BE can be
asymptomatic [3,4]. Grossly, BE is classified on the basis
of its length: long segment (afflicted part of the esopha-
gus is longer than 3 cm), short segment (shorter than 3
cm), and ultra-short segment (which is not actually
observed by the endoscopic examination) [5]. Microsco-
pically, Barrett’s esophagus was defined by the presence
of goblet cells. Today, however, it is accepted that there
are three histologic subtypes of columnar epithelium
which are found near to the distal esophagus [6],
whereas only one of them is characterized by goblet
cells presence. The first type is the junctional type
secreting mucus, the second one is the gastric type of
columnar epithelia with the presence of parietal and
chief cells and the third one called „specialized intestinal
metaplasia“ with the goblet cells presence which is the
most proximal to the squamous epithelium [7].
* Correspondence: jiri.ehrmann@hotmail.com
1Department of Histology and Embryology, Faculty of Medicine and
Dentistry, Palacky University and University Hospital, Hnevotinska 3, 775 15
Olomouc, Czech Republic
Full list of author information is available at the end of the article
Luzna et al. Diagnostic Pathology 2011, 6:114
http://www.diagnosticpathology.org/content/6/1/114
© 2011 Luzna et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.BE can progress through dysplasia stages (low grade
and high grade dysplasias) and even to the esophageal
adenocarcinoma (EAC) [8]. Thus, Barrett’se s o p h a g u s
presents a sequential model of carcinogenesis. The
attention to the EAC diagnosis is outright because of its
rising prevalence in western countries [9] and its extre-
mely high mortality oscillating about 85% within 5 year
period [10].
MicroRNAs
MicroRNAs form a large group of 18-22 nt short single-
stranded RNAs with a high potential of gene expression
regulation [11]. MicroRNAs were discovered as late as
in 1993 by Victor Ambros and his colleagues in the
worm Caenorrhabditis elegans. Successively, microRNAs
were revealed across the plants and other animals
including Homo sapiens. Nowadays, 1100 diverse micro-
RNAs were identified in humans [12]. Due to their size
and properties, they can create complementary bounds
with high amount of mRNAs and therefore block the
process of translation or to degrade the mRNA. It is
estimated that 30% of all human genes are regulated by
them.
It is important and fundamental to note, that their up
and downregulation is correlated to various disorders
including malignant tumors [13,14]. It is presumed that
the huge group of microRNAs is the potential target for
therapy of all sorts of diseases including malignant ones
[15]. There are hundreds of studies monitoring levels of
hundreds of microRNAs in malignant versus healthy tis-
sues and hundreds of studies focused on the functional
role of these molecules in the process of carcinogenesis
[13,14,16-18].
Therefore the aim of this study was to identify a com-
bination of selected microRNAs levels of which (com-
pared to normal healthy individuals) would definitely
characterize a patient with Barrett’s esophagus diagnosis,
even in spite of the fact that the histological examina-
tion is not clear. Further, we wanted to find out if a spe-
cific microRNA which would reflect the grading of the
progression does exist. All the previous studies per-
formed used usually frozen tissue samples and the num-
ber of the examined patients was low [19-22].
Nevertheless, archives of departments of pathology are
offering enough biological material for the retrospective
studies and it was confirmed that FFPE tissues are suita-
ble for routine microRNA levels determination [23-27].
It is well known that the process of carcinogenesis is
generally connected to major important genes involved
in e.g. cell cycle, proliferation or inflammation. That’s
why we explored the miRBase and http://microRNA.org
databases and searched for the concrete microRNAs
which could impact the target genes from the selected
groups. Due to our ongoing immunohistochemical
studies we chose IL-1beta and IL-8 genes, revised the
literature and we found out that they could regulate the
expression of miR-21 resp. miR-203 as well. According
to the literature, miR-192 is tightly connected to the
digestive system carcinomas and miR-196a was found to
have a potential to influence the cell cycle inhibitor p27,
and p27 is mentioned as a colorectal carcinoma progres-
sion marker and pancreatic ductal adenocarcinoma bio-
marker, too. Simultaneously, we discussed our chosen
miRNAs with present literature findings and finally
decided to use four chosen microRNAs.
Methods
Tissue processing and staining
All the experimental and tissue handling approaches
were approved by the Ethical Comittee of the University
Hospital Olomouc. Bioptical specimens of esophageal
mucosa were taken as a part of the regular endoscopic
examination of the BE diagnosis by NBI (narrow band
imaging) and AFI (autofluorescence). Immediatelly after
t h em u c o s ae x c i s i o n ,t h et i s s u ew a si m m e r s e di n t ot h e
Baker’s solution and fixed for 24 hours. Consequently,
after tissue processing it was embedded into paraffin. A
routine H-E staining was performed and the grade of
dysplasia was estimated. Consequently, a histochemical
staining (PAS, Alcian blue) was performed according to
the standard protocol.
Laser capture microdissection (LCM)
All the methodical accesses were held under RNAse free
conditions. We examined 71 patients diagnosed for BE
(12 BE diagnosed macroscopically by NBI - microscopi-
cally not confirmed, 20 BE without dysplasia, 27 with
low grade dysplasia and 12 with high grade dysplasia/
adenocarcinoma). Since this is a retrospective study, the
paraffin blocks originated from years 2006-2010. Paraffin
blocks were cut for 5-6 μm thick slides which were
mounted on the PET membrane-coated metal frame
(before this the frame was exposed to 30 min of UV
light, followed by poly-L-lysin coating in termostat for
30 minutes in 37°C). For better adhesion of the tissue
the frames were put into the incubator for 30 minutes
and 58°C. Concurrently, a routine H-E slide was pre-
pared for better observation and orientation in the tissue
architecture, because the slides used for microdissection
have to be air-dried, thus cellular structures are worse
recognizable.
T h em e m b r a n ec o a t e ds l i d ew i t ht h em o u n t e dt i s s u e
was deparaffinized in two baths of xylene, 3 minutes
each and consequently put into the 100% ethanol.
Further, 95%, 75% and 50% ethanol solutions were used,
30 seconds each. Subsequently, the slides were stained
by the cresyl violet solution for 1 minute, then washed
by the rising concentrations of ethanol (50%, 75%, 95%
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stored under the silicagel. The following LCM process
was performed afterwards immediately.
The PET coated metal frame was turned around and
placed on the basic histological slide and put into the
microdissector. The requested tissue area was marked
and dissected by the UV laser. Immediately after the dis-
section, the microdissected tissue was collected by the
adhesive cap of the special eppendorf tube. We used the
mmi CellCut
® (Molecular Machines & Industries, Zür-
ich, Switzerland) microdissection instrument.
RNA extraction, multiplex reverse transcription,
preamplification step
Immediately after LCM, the eppendorf tube with the tis-
sue was filled by 100 μl of digestion buffer, freezed at
-80°C or RNA was promptly isolated. Prior to the RNA
isolation, protease digestion was performed for 3 hours
in 50°C and 15 minutes for 80°C. RNA including the
small microRNA fragments was extracted by the Reco-
verAll™ Total Nucleic Acid Isolation Kit for FFPE
(Ambion/Applied Biosystems/Life Technologies; Carls-
bad, CA, USA) according to manufacturer’sp r o t o c o l .
The elution volume was 60 μla n di tw a sc o n s e q u e n t l y
spinned in a vacuum concentrator for 1,5 hour to
reduce the final volume to approximately 20 μl. The
concentration of RNA was measured by the NanoDrop
spectrophotometer (Wilmington, DE, USA) and the
yield was moving around 10 ng/μl. The isolated RNA
was subjected to the reverse transcription and eventually
stored at -80°C.
Every reverse transcription reaction contained the
amount of 5 ng of total RNA isolated. The total volume
of the reaction was 7,5 μl and it consisted of 3,5 μlo f
master mix (0,075 μl 100 mM dNTPs with s dTTP; 0,5 μl
MultiScribe™ Reverse Transcriptase, 50 U/μl; 0,75 μl
10× Reverse Transcription Buffer; 0,095 μl RNAse Inhibi-
tor, 20 U/μl; 2,08 μl DEPC water), all from TaqMan
®
MicroRNA Reverse Transcription Kit (Applied Biosys-
tems/Life Technologies; Carlsbad, CA, USA); 2,5 μlR N A
and 1,5 μl RT stem-loop RT-primer pool (10 RT-primers,
concentration 0,5× each: RNU44, RNU48, RNU66,
RNU6B, U47, miR-16, miR-21, miR-192, miR-196a, miR-
203) (all from Applied Biosystems/Life Technologies;
Carlsbad, CA, USA). The reverse transcription reaction
proceeded according to the protocol recommended by
the manufacturer (30 minutes in 16°C, 30 minutes in 42°
C, 5 minutes in 85°C). For the signal transduction the
preamplification step was inserted according to [28].
Real time PCR assay, PCR efficiency, endogenous control
selection
The total volume of the qPCR reaction mixture was 10
μl. The mixture consisted of 5 μlo ft h eT a q M a n
® 2×
Universal Master Mix II No AmpErase UNG, 2 μlo f
nuclease free H2O, 0,5 μl of single TaqMan
® microRNA
assay (all from Applied Biosystems/Life Technologies;
Carlsbad, CA, USA) and 2,5 μl of the preamplification
product. The amplification step was designed according
to the manufacturer’s protocol [95°C for 10 minutes, 45
cycles (95°C for 15 seconds, 60°C for 60 seconds)]. All
the qPCR reactions were performed in the LightCycler
®
480 System (Roche Applied Science, Penzberg,
Germany).
For the efficiency of the qPCR reaction the First-
Choice
® Stomach RNA (Ambion/Applied Biosystems/
Life Technologies; Carlsbad, CA, USA) was used
because BE is a glandular type of metaplasia. Normal
glands are found in stomach which is simultaneously
the examined area during the esophageal endoscopy. So,
the efficiency of PCR reaction should be verified in the
glandular tissue.
The qPCR reaction for the chosen microRNA assay
was adjusted for the 5 RNA template concentrations.
The preamplification step was inserted as well. All the
volumes were the same as for the regular qPCR reac-
tion. After the reaction run, the efficiency was counted
by the plotting the Cp value towards the log of the RNA
concentration. The efficiency was presented by the slope
of the axis.
Each qPCR reaction was performed for 6 potential
endogenous controls (RNU44, RNU48, RNU66, RNU6B,
U47, miR-16) according to the most cited reference
genes in literature [20,29]. The most suitable two endo-
genous controls were assessed by the free downloadable
application geNorm. The latter calculates a gene expres-
sion normalization factor for each tissue sample based
on the geometric mean of a user-defined number of
reference genes [30,31].
Statistical analysis
The results of the study were processed by the biostatis-
tician. The Kruskal-Wallis test with the multiple com-
parison was used for the p value formulation. In the
regression relations (grading compared to other chosen
parameters) the test of the coefficient significance in the
regression model was used [32].
Fold changes
The results of the experiments are presented as the x-
fold change. It is the ratio of the relative gene expres-
sions (relative expression of the examined gene in the
sample and relative expression of this gene in the cali-
brator - normal healthy esophagus). The relative gene
expression is the expression of the target gene divided
by the expression of the reference (housekeeping) gene.
The number of the fold expresses how many times is
t h er e l a t i v ee x p r e s s i o no ft h et a r g e tg e n eh i g h e ro r
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the calibrator. The x-fold is expressed by formula [33]:
ratio =
(ERef)
CPsample
(Etarget)
CPsample ÷
(ERef)
CPcalibrator
(Etarget)
CPcalibrator
cp = threshold point
E = efficiency of the qPCR reaction
sample = Barrett’s esophagus in any grade
calibrator = normal healthy esophageal epithelium
On the basis of geNorm, reference genes RNU44 and
U47 were used and all the x-fold changes are relativized
to their geometrical mean.
Results and discussion
In the case of miR-21, no statistically significant differ-
ences between Barrett’s esophagus and normal epithelia
were acquired (see Figure 1). Refering to miR-192, there
is a statistically significant upregulation of miR-192
expression in any grade of the disease with the p <
0,00001 (see Figure 2). miR-196a expression shows the
upregulation as well with p < 0,05 (see Figure 3). On
the other hand, miR-203 is definitely downregulated in
the impaired tissue with the p < 0,00001 (see Figure 4).
In the case of miR-196a, there is a statistically significant
(p < 0,005) trend in relative expression dependent on
the disease grading (see Figure 5). The results acquired
from the analysis of disease grading did not confirm the
dependency on sex, hiatal hernia, obesity, smoking, alco-
hol abuse, family anamnesis of any cancer, each of this
risk factor being estimated separately (Pearsons Chi-
Quadrat Test with Monte Carlo Simulations). Kruskal-
Wallis Chi-Quadrat Test did not confirm the correlation
of the grading versus age of patients as well as it did not
confirm the correlation of the grading versus alcohol
and smoking (every risk factor considered separately).
However, correlation of grading versus hiatal hernia,
obesity, smoking, alcohol abuse, family anamnesis (all
parameters considered together) has confirmed that
there are statistically significant parameters for alcohol
(p < 0,046) and smoking (p < 0,065). Further, the corre-
lation of grading to all the previous parameters plus sex
and age shows statistically significant values of the influ-
ence of sex (p < 0,008), age (p < 0,065), smoking (p <
0,02), and alcohol abuse (p < 0,0045).
Figure 1 miRNA-21 expression in normal healthy esophagus vs
Barrett’s metaplasia. No statistically significant differences in miR-
21 expression were observed.
Figure 2 miRNA-192 statistically significant upregulation in BE
patients.
Figure 3 miRNA-196a upregulation in BE patients is statistically
significant.
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basis of chronic inflammation [34,35] which originates
as a reaction to the gastroesophageal reflux disease
(GERD). GERD occurs when the acid content of the sto-
mach returns to the distal part of the esophagus. The
continuous irritation of the esophageal squamous strati-
fied nonkeratinized epithelium induces its replacement
by the columnar one which is less mechanically resistant
but it resists to the low pH of the esophageal microen-
vironment. Connection between BE and GERD was well
established in the 1970s [6,36]. However, when there is
GERD in the esophagus, BE must not be necessary pre-
sent. GERD is not the only risk factor for development
of BE. It is the presence of hiatal hernia, obesity (visceral
fat), smoking or alcohol abuse as well. Moreover, men
are three times more in danger than women. O’Riordan
et al. [34] demonstrated that in the inflammation - BE -
EAC sequence the levels of proinflammatory cytokines
IL-8 and IL-1b increase. Thus, interleukins seem to be
one possible target of the therapeutic intervention in the
future. Another possible target of BE therapy could be
the microRNAs - short single-stranded molecules with
high potential of gene regulation.
It is well known that many microRNAs are deregu-
lated in the connection with malignant progression.
Changes in microRNA-196a expression are cited in con-
nection with both pancreatic adenocarcinoma and breast
carcinoma as well as in Barrett’s esophagus. In combina-
tion with another miRNA (miR-217), miR-196a level can
help distinguish between malignant and benign pancrea-
tic tissue [37]. Moreover, in long-term survival adeno-
carcinoma patients (24 months), the levels of miR-196a
are conversely correlated with survival [38]. As well as
Mathé et al. [21], we also revealed that microRNA-196a
is definitely overexpressed in Barrett’s esophagus of any
grade compared to normal healthy esophageal tissue,
even the statistical analysis shows that the trend of the
rising expression of this microRNA during the BE pro-
gression does exist. Moreover, compared to [20] (11
FFPE patients), we demonstrated this fact in our study
with 71 patients in 4 gradings of BE.
In the case of miR-21, it was published, that six solid
tumor tissues (lung, breast, stomach, prostate, colon,
pancreas) where miR-21 is t h eo n l yo v e r e x p r e s s e d
microRNA do exist [39]. Feber et al. [19] describes the
overexpresson of miR-21 and downexpression of miR-
203 in his experiments with Barrett’s esophagus as well
as with esophageal adenocarcinoma. In the paper from
Saini et al. [40], microRNA-203 is described as a anti-
metastatic small RNA with the possible therapeutic
intervention. Our results suggest the unequivocal miR-
203 downregulation in BE, but non-unequivocal miR-21
expression. Compared to our study, Feber performed his
experiments for 35 frozen specimens without the micro-
dissection step. The same conclusion (for miR-21 and
miR-203) can be find in the paper from Mathé et al.
[22] who compared miRNA expression profiles of eso-
phageal adenocarcinoma and squamous cell carcinoma
to the adjacent noncancerous tissue pairs. In addition,
Mathé et al. [22] describe the elevation of levels of miR-
192 in esophageal adenocarcinoma. In our set of
patients, we have come to the same conclusion.
Dealing with the possibility of getting the tissue sam-
ples through all stages of BE progression in one
Figure 4 Statistically significant downregulation of miR-203 in
BE patients correlated to normal healthy esophageal tissue.
Figure 5 Rising miRNA-196a upregulation in BE patients in NBI
detected BE(1), BE(2), low-grade dysplasia(3), high-grade
dysplasia/adenocarcinoma(4).
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in obtaining of tissue samples from all stages of BE pro-
gression in one patient’s case, however we have to point
out that the NBI technique, which we are using in the
endoscopic examination helps to vizualize the architec-
ture of the BE lesion and gives us the most precise pic-
ture of the stage of potential dysplasia and if there are
any indications of proliferation to higher stage of BE
dysplasia, it is therapeutically intervened. Our aim is not
to let the patient to escalate to HGD/EAC stage which
is very difficult to cure.
Most of the gene expression studies cited deal with
relative expression data, but not all of them deal with
the endogenous controls. Nonn et al. [28] use the nor-
malization of the results to two chosen small nucleolar
RNA RNU44 and RNU48, Maru et al. [21] use miRNA-
16 as the reference gene. In his Application Note
(Applied Biosystems/Life Technologies; Carlsbad, CA,
USA) Wong et al., 2007 describe all the applicable endo-
genous controls suitable for microRNA data normaliza-
tion, however with the necessity of verification. That’s
why in this paper six possible endogenous controls were
chosen and the most stable couple of them was chosen
for relative expression data calculation.
Conclusions
In our study, we showed that there possibly do exist
such combinations of microRNA expressions of which
may be able to give us an information about the
patient’s status and possible disease progression. Expres-
sion of microRNA-196a was unequivocally confirmed as
the Barrett’s esophagus molecular marker with the rising
trend through the disease progression. In combination
with expression of microRNA-192 and microRNA-203
the patient could be independently diagnosed and his
diagnosis could be confirmed in spite the fact that the
BE diagnosis is not supported by the histological
examination.
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